Inventor · disambiguated record
Donald Zack
Also filed as: ZACK DONALD · ZACK DONALD J · ZACK DONALD JEFFERY · ZACK DONALD JEFFREY
17 granted patents·14 pending applications·104 citations·filing 2000–2023
93Inventor score
Files withUNIV JOHNS HOPKINS24ZACK DONALD J3KERRISON JOHN BARNWELL1THE JOHNSON HOPKINS UNIV1UNIV CALIFORNIA1
Top patents by PatentIndex Score
31 records- 0191US9539259B2Compounds and methods of use thereof for treating neurodegenerative disordersUNIV JOHNS HOPKINS·Filed 2013·Granted Jan 10, 2017·18 cites·38 claims
- 0291US6479729B1Mouse model for ocular neovascularizationUNIV JOHNS HOPKINS·Filed 2000·Granted Nov 12, 2002·28 cites·16 claims
- 0390US9907863B2Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoterUNIV JOHNS HOPKINS·Filed 2015·Granted Mar 6, 2018·5 cites·6 claims
- 0490US9655882B2Compositions and methods for treatment of neurodegenerative diseaseUNIV JOHNS HOPKINS·Filed 2015·Granted May 23, 2017·6 cites·8 claims
- 0590US8993615B2Compositions and methods for treatment of neurodegenerative diseaseZACK DONALD J·Filed 2009·Granted Mar 31, 2015·16 cites·3 claims
- 0689US11013719B2Sunitinib formulations and methods for use thereof in treatment of glaucomaUNIV JOHNS HOPKINS·Filed 2019·Granted May 25, 2021·2 cites·9 claims
- 0789US10369234B2Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoterUNIV JOHNS HOPKINS·Filed 2018·Granted Aug 6, 2019·3 cites·6 claims
- 0889US9162981B2Compositions and methods for treatment of neurodegenerative diseaseZACK DONALD J·Filed 2011·Granted Oct 20, 2015·7 cites·27 claims
- 0988US9382229B2Compounds and methods of use thereof for treating neurodegenerative disordersZACK DONALD J·Filed 2012·Granted Jul 5, 2016·6 cites·2 claims
- 1087US10668173B2Compositions and methods for the expression of CRISPR guide RNAS using the H1 promoterUNIV JOHNS HOPKINS·Filed 2019·Granted Jun 2, 2020·2 cites·7 claims
- 1187US10406245B2Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoterUNIV JOHNS HOPKINS·Filed 2018·Granted Sep 10, 2019·2 cites·6 claims
- 1286US10525034B2Sunitinib formulations and methods for use thereof in treatment of glaucomaUNIV JOHNS HOPKINS·Filed 2015·Granted Jan 7, 2020·5 cites·14 claims
- 1382US9539239B1Compositions and methods for treatment of neurodegenerative diseaseZACK DONALD JEFFREY·Filed 2015·Granted Jan 10, 2017·3 cites·25 claims
- 1478US11766488B2Compositions and methods comprising improvements of CRISPR guide RNAS using the H1 promoterUNIV JOHNS HOPKINS·Filed 2017·Granted Sep 26, 2023·1 cites·19 claims
- 1575US2024336934A1Crispr/cas9-based compositions and methods for treating retinal degenerationsUNIV JOHNS HOPKINS·Filed 2023·Application pending·0 cites
- 1670US11896679B2Compositions and methods for the expression of CRISPR guide RNAs using the H1 promoterUNIV JOHNS HOPKINS·Filed 2020·Granted Feb 13, 2024·0 cites·6 claims
- 1768US2021251959A1Sunitinib formulations and methods for use thereof in treatment of glaucomaUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 1867US2022090086A1Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disordersUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 1965US11180760B2Identification of molecular pathways and methods of use thereof for treating retinal neurodegeneration and other neurodegenerative disordersUNIV JOHNS HOPKINS·Filed 2013·Granted Nov 23, 2021·0 cites·6 claims
- 2062US2025092391A1Promoters for viral-based gene therapyUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 2156US2023382904A1SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOFUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 2256US2023304069A1Methods and compositions for single cell analysisUNIV JOHNS HOPKINS·Filed 2021·Application pending·0 cites
- 2355US2020080108A1Crispr/cas9-based compositions and methods for treating retinal degenerationsUNIV JOHNS HOPKINS·Filed 2017·Application pending·0 cites
- 2452US2004086511A1Neuronal gene expression patternsUNIV JOHNS HOPKINS·Filed 2003·Application pending·0 cites
- 2551US2023002790A1POLY(Beta-AMINO ESTER) NANOPARTICLES FOR THE NON-VIRAL DELIVERY OF PLASMID DNA FOR GENE EDITING AND RETINAL GENE THERAPYUNIV JOHNS HOPKINS·Filed 2019·Application pending·0 cites
- 2650US2023086702A1Substituted 2-amino-pyrazolyl-[1,2,4]triazolo[1,5a]pyridine derivatives and use thereofUNIV JOHNS HOPKINS·Filed 2020·Application pending·0 cites
- 2749US2004081652A1Neuronal and optic nerve gene expression patternsUNIV JOHNS HOPKINS·Filed 2003·Application pending·0 cites
- 2848US2004180048A1Neuronal and retinal gene expression patternsUNIV JOHNS HOPKINS·Filed 2003·Application pending·0 cites
- 2941US2020069818A1Crispr/cas9-based compositions and methods for treating cancerTHE JOHNSON HOPKINS UNIV·Filed 2017·Application pending·0 cites
- 3031US2020010854A1Crispr/cas9-based treatmentsUNIV JOHNS HOPKINS·Filed 2016·Application pending·0 cites
- 3125US9771331B2Methods of identifying neuroprotective compounds for retinal ganglion cellsKERRISON JOHN BARNWELL·Filed 2006·Granted Sep 26, 2017·0 cites·4 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →